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Recently accumulated data provided evidence that cytokines
modulate and/or mediate many essential biological processes,
in particular those concerned with cell growth and
differentiation. These molecules are also mandatory for the
regulation of numerous inflammatory and physiological
states by displaying a broad range of biological properties.
The term biological response modifier that has been applied
to the substances belonging to this group extensively encom-
passes the wide spectrum of activities covered by these
molecules. A single cytokine may have multiple effects both
in vivo and in vitro, with these properties often overlapping
each other and the final result being the sum of the actions of
different factors. One of these molecules with pleiomorphic
functions is tumour necrosis factor (TNF).
The name assigned to TNF is descriptive of the historical
activity of this cytokine and nowadays does not reflect the
true spectrum of its biological activity. Lymphotoxin was
initially discovered as a cytotoxic factor produced by T cells
(Granger & Williams, 1968) and then the term TNF was
introduced to describe a serum protein produced after
bacterial infections which is capable of causing haemorrhagic
necrosis of animal tumours (Carswell et al., 1975). It is also
named cachectin because this molecule was originally isolated
during a series of studies aimed at addressing the problem of
cachexia in chronic disease states. Two proteins have been
characterized and are available as recombinant DNA derived
proteins. They are referred to as TNF (or TNF-alpha), which
is predominantly derived from macrophages, and lym-
photoxin (or TNF-beta) which is a product of activated
lymphocytes.
In the late nineteenth century Coley (1893) observed that
patients with streptococcal infection could have partial remis-
sion of concurrent malignancies. Although other European
investigators noted a link between bacterial infections and
cancer remission before Coley, this is the first observation
related to the description of TNF. It has been subsequently
demonstrated that the bacterial lipopolysaccaride (LPS) was
able to trigger the production of a serum factor leading to
tumour necrosis without causing shock and widespread tissue
injury (Shear, 1944). Further investigation showed that LPS
elicits the production of a host protein capable of inducing
the haemorrhagic necrosis oftumours (O'Malley et al., 1962).
The molecule was characterised in the mid 1970s (Carswell et
al., 1975) and the material has been eventually sequenced and
cloned in the mid 1980s (Pennica et al., 1984).
TNF and lymphotoxin represent two important mediators
in immunity and inflammation. They have a wide range of
effects, including modulation of properties of vascular
endothelium, induction of other cytokines, induction of
antiviral activity, stimulation of bone resorption, angio-
genesis and fibroblast growth. Following a brief description
of the general properties of TNF, I will analyse the basic
functions of this cytokine, notably: (1) its role in tumour cell
cytotoxicity and/or growth; (2) its immuno-modulatory
activity; and (3) its role in inflammatory responses.
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General properties of TNF
The production of TNF is not unique to a particular cell
type. In fact, although the major source of this cytokine is
macrophages (Beutler & Cerami, 1987; Le & Vilcek, 1987;
Aggarwel et al., 1985), the molecule can also be released by
other cell types. These include monocytes stimulated by
gamma interferon (Beutler & Cerami, 1987), T lymphocytes
and T cell lines following stimulation with phorbol esters and
anti-CD3 antibodies in different combinations (Granger &
Williams, 1968; Cutri et al., 1987; Scheurich et al., 1987;
Sung et al., 1988a; Turner et al., 1987), B lymphocytes
(Williamson et al., 1983; Sung et al., 1988b), large granular
lymphocytes (Ostensen et al., 1987; Peters et al., 1986) and
mast cells (Young et al., 1987).
The challenge with LPS appears to be the classical induc-
ing agent for the release of TNF (Nedwin et al., 1985b).
Other stimulators acting in vivo include BCG, Coryne-
bacterium parvum, Brucella abortus and interferon gamma
(Nedwin et al., 1985b; Old, 1985; Clark, 1982). As far as the
regulation of the production of TNF in vitro is concerned,
many stimuli cause cells to release TNF, including the bind-
ing of immunecomplexes and phagocytosis by mononuclear
phagocytes, interferon gamma, interleukin-2 (IL-2), CSF-1,
endotoxin, phorbol esters and viruses (Warren & Ralph,
1986; Strieter et al., 1989b; Beutler & Cerami, 1987, 1988).
Prostaglandins have demonstrated a suppressive effect on the
release of macrophage-derived TNF production (Kunkel et
al., 1986, 1988) and glucocorticoids have been proved to
suppress the transcription of TNF (Remick et al., 1989).
Peripheral blood monocytes and macrophages from different
tissues exhibit both a different ability to express and release
TNF after in vitro challenge and a different responsiveness to
immunomodulators (Martinet et al., 1989; Strieter et al.,
1989a). A differential regulation of TNF-alpha in human
alveolar macrophages and peripheral blood monocytes has
been documented (Strieter et al., 1989b). In fact, prostaglan-
dins and corticosteroids serve as potent regulators of LPS-
induced TNF from peripheral blood monocytes, while
alveolar macrophages are relatively refractory to these sup-
pressive immunomodulating agents (Strieter et al., 1989b).
The genes for both TNF-alpha and TNF-beta are
separated by about I kb of DNA on chromosome 6 within
the major histocompatibility complex (Nedwin et al., 1985a;
Spies et al., 1986). The expression of TNF mRNA encodes a
precursor of 233 amino acids that is processed to a mature
non-glycosylated protein of 17,300 Da containing a single
disulphide linkage (Wang et al., 1985). Recent evidence has
been provided favouring the suggestion that TNF-alpha may
exist in dimeric or trimeric forms, each subunit of which
consisting of an anti-parallel beta-sandwich (Smith & Bag-
lioni, 1987; Jones et al., 1989). The main chain fold ofa TNF
subunit shows a remarkable similarity to the 'jelly-roll' struc-
tural motif characteristics of viral coat proteins (Jones et al.,
1989).
Different cell types, usually following in vitro activation,
possess the receptors for TNF, including macrophages, lym-
phocytes, polymorphonuclear cells, fibroblasts, endothelial
cells, synovial cells, muscle cells, adipocytes, myeloblasts and
tumour cells (Beutler et al., 1985b; Beutler & Cerami, 1988;
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Kull et al., 1985). However, there is no correlation between
the number of receptors and cell susceptibility, the cytolytic
effect of TNF being dependent on the affinity of specific
receptors (Kull et al., 1985; Tsujimoto et al., 1986; Lehemann
et al., 1986). For instance, polymorphonuclear leukocytes
possess as much TNF receptors as tumour cell lines suscepti-
ble to cytolysis but they are not lysed (Larrick et al., 1987;
Tsujimoto et al., 1986; Ruggiero et al., 1987). Internalisation
of TNF and/or its receptors appears to be required for
mediation of cytotoxicity, with the ligand being degraded via
a lysosomally dependent mechanism (Baglioni et al., 1985;
Kull et al., 1985). Despite the fact that TNF and IL-1 are
cytokines with multiple overlapping activities, TNF does not
compete with the IL-1 binding to its receptors (Matsushima
et al., 1986).
The activity on tumour cells
From an historical point of view, TNF was first identified for
its anti-cancer activity. The biological activity of TNF was
detected both by its in vitro cytotoxic effects on certain
sensitive target cells, e.g. L-929 fibroblast-like line and U937
cells, and by its ability to induce the necrosis of Meth A
sarcoma subcutaneously transplanted in mice. The story of
TNF begins in the late nineteenth century when Coley had
some success treating cancer patients by infecting them with
live bacteria. It must be remembered, however, that at that
time, i.e. the pre-antibiotics era, it was difficult to control
infections resulting from bacteria. To prevent this
inconvenience, the above investigator developed the so-called
Coley's toxins, i.e. filtered supernatants from cultures of
erisypeles lesions and Bacillus prodigius. As a matter of fact,
these toxins could be administered without evidence of infec-
tions and the overall results were impressive (Coley Nauts et
al., 1953). Radiotherapy and chemotherapy then became
available and, as a consequence, this type of approach was
completely abandoned.
Availability of highly purified TNF prepared by recom-
binant DNA techniques allowed a better clarification of
biological effects of TNF on tumour cell lines. A wide
variability of behaviour has been displayed by different
tumour cell lines with regard to the cytotoxic or cytostatic
action of this molecule (Ortaldo et al., 1986; Sugarman et al.,
1985; Wang et al., 1985; Tsujimoto et al., 1985). This
variability has been proved to be independent of the number
or affinity of TNF receptors, suggesting that a defect in the
signal transduction mechanisms leading to the cytotoxic res-
ponse might take place in unsensitive cells (Shepard & Lewis,
1988). Free radical generation during the TNF dependent
conversion of arachidonic acid to prostaglandins and intra-
cellular release of lysosomal enzymes have been thought to
represent the crucial mechanisms accounting for the efficacy
of killing capacity (Ruddle, 1987). The resistance of normal
cells and many of the tumour cell lines to TNF is not due to
a lack of TNF receptors or to a low binding affinity for the
ligand, but to the absence of some biochemical signals
elicited in sensitive cells after TNF binding to the receptors
that are responsible for the cytolytic action (Sugarman et al.,
1985). Interestingly, the TNF resistance might be associated
with the production of TNF by the resistant cells (Rubin et
al., 1986; Spriggs et al., 1987). It has also been suggested that
the transforming growth factors which are produced by
different tumour cell lines may protect the tumour cell from
destruction by TNF-alpha in vivo (Shepard & Lewis, 1988).
The finding that TNF can also destroy tumours in vivo
even in the absence of a direct lytic effect of neoplastic cells
in vitro has led to the hypothesis that TNF is able to display
an indirect action. In fact, experimentally induced neoplasias
generated from tumour cells not susceptible to the action of
TNF in vitro are rapidly destroyed. Since tumour destruction
takes place only in vascularised neoplasias, the indirect action
seems to be mediated by the efficacy of TNF on the vascular
endothelium of the tumour circulation (Palladino et al.,
1987.)
TNF has demonstrated a selective toxicity for leukaemic
cells in myeloid leukaemias (Prince et al., 1987). In this
regard, the colony formation by clonogenic cells freshly
derived from patients with acute myelogenous leukaemia,
myeloid blast crisis of chronic myelogenous leukaemia, or
chronic myelomonocytic leukaemia, was suppressed to
various degrees by the presence of TNF-alpha. This suggests
that the action of rTNF-alpha in myelogenous leukaemias
could be exploited therapeutically and the dose-time res-
ponse relationship should be considered in designing treat-
ment schedules (Beran et al., 1988).
Interestingly, TNF has also been demonstrated to act as a
tumour growth factor in a dose-dependent manner for
chronic B-cell malignancies and in particular for leukaemic
hairy cells (Cordingley et al., 1988a; Buck et al., 1988; Tren-
tin et al., 1989). It has been shown to promote the prolifera-
tion of leukaemic cells and to induce TNF mRNA protein,
thus supporting the concept of an autocrine model of tumour
cell proliferation (Cordingley et al., 1988a).
TNF has also been shown to modify the susceptibility of
leukaemic cells to the lysis by autologous or allogenic
cytotoxic lymphocytes. In fact, the demonstration has been
provided that TNF, in association with INF-y, increases the
susceptibility of hairy cell leukaemia to natural killer (NK)
cell lysis. This synergism is not mediated by a INF-y induced
increase in TNF receptors on hairy cells and therefore it
seems to occur at a post-receptor level (Cordingley et al.,
1988b).
The inflammatory activity
Several cell-to-cell communications are crucial during the
initiation, maintenance and resolution of specific foci of
inflammation. Lymphokines act as local mediators of cellular
homeostasis and TNF plays a key role among these various
cytokines.
One of the most important events that occurs during a
local immune inflammatory response is represented by the
effect of TNF on the endothelial surface. It is well known
that the endothelial cell does not represent a bystander target
cell but plays a crucial role during the immune responses. In
this regard, TNF has been shown to stimulate the
angiogenesis (Leibovich et al., 1987) and to alter the
endothelial cell responsiveness (Gamble et al., 1985; Broudy
et al., 1987). In addition, TNF stimulates human vascular
endothelial cells to release neutrophil chemotactic factors and
to promote the transendothelial neutrophil influx (Moser et
al., 1988; Strieter et al., 1988). It is worth mentioning that
other cytokines, particularly IL-1 and INF-o, ,, and y, play
an important role in regulating the endothelial responsiveness
(Pober et al., 1986; Moser et al., 1988). Furthermore, TNF
increases the expression of class I major histocompatibility
complex (MHC) antigens on the vascular endothelium sur-
face (Gamble et al., 1985; Pohlman et al., 1986). It also
increases the production of procoagulants and down-
regulates the production of thrombomodulin, thus converting
vascular endothelium to a procoagulant surface (Stern &
Nawaroth, 1986; Bevilacqua et al., 1986). In fact, throm-
bomodulin binds to serum proteins S and C to promote local
anti-coagulation. This finding, in association with the
capacity of TNF to induce inflammatory cell adherence to
vessel walls (Nawroth & Stern, 1986; Taylor et al., 1987),
represents an additional factor contributing to a coagulant
state with cessation of blood flow and then leading to tissue
necrosis.
TNF induces the trapping of neutrophils in localised areas,
thus initiating the inflammatory response. In fact, TNF has
chemotactic activity that may serve to recruit phagocytic cells
from the blood compartment to amplify resistance against
noxious agents (Ming etal., 1987). During an inflammatory
reaction, TNF allows neutrophils to respond more efficiently
to an invasive agent by increasing their property to
phagocytose (Klebanoff et al., 1986) and by activating the
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immune process has been initiated, TNF induces an oxidative
burst, degranulation and increased phagocytic activity
(Shalaby et al., 1985; Klebanoff et al., 1986).
TNF induces fever initially by increasing prostaglandin E2
synthesis in the hypothalamus and subsequently by triggering
the production of IL-1 (Dinarello et al., 1986; Nawroth et al.,
1987). Other factors produced in response to the TNF in-
clude platelet-derived growth factor (Hajjar et al., 1987),
platelet-activating factor (Camussi et al., 1987), prostacyclin
(Kawakami et al., 1986), osteoclasts activating factor (Dew-
hirst et al., 1985; Bertolini et al., 1986), and haematopoietic
growth factors, including G-CSF and GM-CSF (Broudy et
al., 1987; Munker et al., 1986; Trinchieri et al., 1986; Zucali
et al., 1988).
TNF has also been implicated in the remodelling of con-
nective tissue through an action on fibroblasts. In fact, TNF
induces fibroblasts to grow (Vilcek et al., 1986) and to pro-
duce IL-1 (Le et al., 1987), colony stimulating factors (Zucali
et al., 1987), interferon beta-2 (Van Damme et al., 1987) and
glycosaminoglycans (Elias et al., 1988). TNF has been found
to be capable of stimulating collagenase and PGE2 produc-
tion by isolated synovial cells and dermal fibroblasts (Dayer
et al., 1985).
The evidence that mice passively immunised against the
hormone are protected against the lethal effect of
lypopolysaccaride suggested a primary role of TNF as a
mediator of endotoxic shock (Beutler et al., 1985c). When
TNF became available in the recombinant form, and thus in
preparations free of contaminating endotoxin, it was possible
to demonstrate that TNF itself is able to induce the shock
and the tissue injury usually associated with endotoxaemia
(Tracey et al., 1985).
Rats infused with recombinant TNF presented with diarr-
hoea, piloerection, haemoconcentration, shock, metabolic
acidosis and hyperglycaemia followed by hypoglycaemia.
Leucostasis, oedema, ischaemic and haemorrhagic lesions
have been documented in different organs, including the lung,
kidney, adrenal tissue, pancreas and gastrointestinal tract.
Furthermore, it has been subsequently demonstrated that
non-human primates can be protected against the lethal
effects of endotoxin injection by pre-treatment with anti-TNF
antibody (Tracey et al., 1987). TNF has also been demon-
strated to contribute to the pathogenesis of septic acute lung
injury by producing increased pulmonary permeability and
oedema (Stephens et al., 1988).
The observation that trypanosome-infected rabbits develop
an hypertriglyceridaemia associated with suppression of the
enzyme lipoprotein lipase (Rouzer et al., 1980) led to the
discovery that a murine macrophage mediator, released
under the action of LPS or other invasive stimuli, was able to
suppress the lipoprotein lipase expression in the fatty tissues
of mice and in cultured adipocytes (Kawakami & Cerami,
1981; Kawakami et al., 1987). This factor was called cachec-
tin and subsequent evaluations revealed that the sequence of
cachectin and TNF were indistinguishable (Beutler et al.,
1985a). As a matter of fact, in experimental models it has
been demonstrated that nude mice injected with cells con-
stitutionally secreting TNF develop anorexia, weight loss and
anaemia (Oliff et al., 1987).
The immunomodulatory activity
TNF has been demonstrated to display a series of species-
specific effects on different cell types and functions. With
regard to the monocyte/macrophage lineage, TNF provides
important mechanisms to augment the effector activities of
these cells at inflammatory foci. In particular, TNF enhances
the cytotoxicity of macrophages (Philip et al., 1986), induces
the synthesis ofinterleukin-l (Bachwich et al., 1986a) and the
expression of Fc receptors (Hoffman & Weinberg, 1987), and
of Ia antigens (Chang & Lee, 1986). TNF also enhances the
production of hydrogen peroxide (Hoffman & Weinberg,
1987), the synthesis of increased levels of platelet activating
factor and prostaglandin E2 (Bachwich et al., 1986a; Camussi
et al., 1987).
The action of TNF on lymphocytes is displayed after the
initial stimulation of T cells because resting T lymphocytes
appear to lack the TNF receptors (Kull et al., 1985). TNF
can stimulate T lymphocytes in a dose-dependent manner
(Zucali et al., 1987) and it also modulates the proliferation
and differentiation of B lymphocytes (Jelinek & Lipskey,
1987; Kashiwa et al., 1987; Kehrl et al., 1987). TNF enhances
the IL-2R expression on a lymphoblastic null-cell leukaemic
line in a fashion similar to that of IL-1 (Lee et al., 1987).
High concentrations of TNF induce T lymphocytes to release
interferon gamma and TNF provides a synergistic effect with
IL-2 in the generation of LAK cells (Owen-Schaub et al.,
1988; Chouaib et al., 1988; Yang et al., 1989).
TNF induces neutrophils to produce hydrogen peroxide
(Shau, 1988) and stimulates human vascular endothelial cells
to promote transendothelial neutrophil passage (Moser et al.,
1988).
TNF has been demonstrated to exert an anti-viral effect in
vitro, which is mediated through the induction of IFN-beta.
In fact, Kohase et al. (1986) and Mestan et al. (1986) showed
that recombinant human TNF can produce an anti-viral
effect in human diploid fibroblasts. This action of TNF could
be abolished in the presence of antiserum specific for IFN-
beta. By contrast, Wong & Goeddel (1986) suggested that the
anti-viral action of TNF does not involve IFN as an
intermediate. It has been demonstrated that cachectin/TNF
selectively kills cells infected with herpes simplex virus (Koff
& Fann, 1986), thus attributing a protective role to TNF.
TNF-alpha is also able to stimulate the HIV enhancer by
activation of the NF-kB transcription factor (Osborn et al.,
1989).
Diseases in which an increase of TNF has been found
As far as experimental models are concerned, TNF has been
proved to play an important role in the pathogenesis of
cerebral malaria (Grau et al., 1987) and to represent an
effector of the skin and gut lesions of the acute phase of graft
versus host disease (Piguet et al., 1987). Furthermore, a
relationship between BCG-induced granulomas and TNF
synthesis has been recently reported (Kindler et al., 1989). In
these murine models, the in vivo treatment with an anti-TNF
antibody resulted in an almost complete prevention of the
above quoted lesions (Grau et al., 1987; Piguet et al., 1987;
Kindler et al., 1989). These latter findings suggest the
hypothesis that the therapeutic possibilities of antibodies or
specific antagonists against TNF should be taken into
account.
The pleiomorphic effects of TNF on different target cells
place this molecule in a pivotal role in modulating acute and
chronic disease states. For this reason, the levels of TNF
activity have been evaluated in different clinical conditions.
No TNF activity was detected in blood cell extracts (Hofsli
et al., 1988) but TNF mRNA may be present in vivo (Tovey
et al., 1988).
The role of TNF in the pathogenesis of the cachexia
associated with human chronic diseases remains to be deter-
mined since TNF cannot be detected in the plasma of cachec-
tic patients. This may be consequent to the low sensitivity of
assays presently available (Beutler & Cerami, 1987). As a
matter of fact, a discrepancy has been observed in different
biological and enzymatic assays which still need to be solved
(Balkwill et al., 1987a; Duncombe et al 1988; Fomsgaard et
al., 1988; Munck Petersen & Moller, 1988).
Increased levels of TNF were associated with poor prog-
nosis in patients with meningococcal infections (Waage et al.,
1987; Girardin et al., 1988). Serum levels of TNF-alpha were
positively correlated with the number of risk factors and
negatively correlated with blood fibrinogen levels, thus
indicating that TNF correlates with the severity of menin-
gococcaemia in children (Girardin et al., 1988). Lipopolysac-
charide exposed monocytes from patients with previous Yer-
sinia arthritis secrete significantly more TNF than controls
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Increased plasma levels of TNF has been observed in
patients with sarcoidosis (Bachwich et al., 1986b; Spatafora
et al., 1989), parasitic infections (Scuderi et al., 1986) and
autoimmune disorders (Turner et al., 87). Among patients
with malignancies, high serum levels of TNF have been
found in patients with cancer (Balkwill et al., 1987), chronic
lymphocytic leukaemia (Hahn et al., 1989), and hairy cell
leukaemia (Buck et al., 1988; Lindemann et al., 1989). In
addition, TNF mRNA has been demonstrated on hairy cells
stimulated in vitro with TNF (Cordingley et al., 1988a).
Furthermore, the potential role of TNF as the mediator
responsible for the extensive marrow necrosis found in
patients with cancer has been suggested (Knupp et al., 1988).
Increased levels of TNF have been described in the serum
of patients with AIDS; this finding has been claimed to be
relevant to the pathogenesis of cachexia in this disease
(Lahdevirta et al., 1988). Moreover, TNF-alpha levels were
significantly higher in supernatants obtained by monocytes
isolated from asymptomatic HIV-infected patients as com-
pared to normal controls (Wright et al., 1988; Roux-
Lombard et al., 1989). In this regard, conflicting results have
been reported in a previous paper by Ammann et al. (1987).
An increase in TNF production by alveolar macrophages
recovered from the bronchoalveolar lavage in HIV infect-
ed patients has also been demonstrated (Agostini et al.,
1989).
In vivo use of TNF: present status and future directions
In rabbits it has been shown that TNF is cleared from the
plasma with a half-life of 6-7 min (Beutler et al., 1985b).
Studies on the tissue distribution of labelled TNF after injec-
tion have demonstrated that liver, kidneys, skin and gast-
rointestinal tract take up most of the lymphokine (Beutler et
al., 1985b). Studies with TNF, in association with IFN-y,
have also been performed in experimental ovarian cancer
showing a significant activity (Balkwill et al., 1987). A regres-
sion of a murine sarcoma has been observed after in vivo
treatment with recombinant human TNF and this effect has
been found to be obtained via Lyt-2 + cells (Asher et al.,
1989).
The evidence accumulated in the animal models that the
immune system can be manipulated to mediate the regression
of established growing tumours, coupled to the availability of
TNF produced through recombinant DNA technology, has
enabled the exploration of the potential therapeutical
benefits of TNF as an anti-neoplastic agent in human
beings.
Phase I studies, in which TNF-alpha was given in a variety
of schedules (single dose, continuous 5 days infusion, daily
for 5 days, etc.) with doses increasing from 1 to 400 jig m2,
indicated that the maximum tolerated dose of TNF seems to
be 200tg m-2 (Blick et al., 1987; Chapman et al., 1987;
Creaven et al., 1987, 1989; Sherman et al., 1988). TNF was
administered by the intravenous and subcutaneous rute
(Chapman et al., 1987). The half-line of rTNF administered
intravenously was 20 min. Side-effects include fever, chills,
rigor, fatigue, diarrhoea, headache, nausea and vomiting,
severe hypotension, and fluid retention most likely conse-
quent to a capillary-leakage syndrome similar to that de-
scribed for IL-2 (Chapman et al., 1987; Creaven et al., 1987;
Kimura et al., 1987; Mortiz et al., 1989; Sherman et al.,
1988). However, fluid accumulation is much less prominent
with TNF as compared to the retention observed during IL-2
therapy. In a few patients a transient elevation of tran-
saminases has been observed but hepatic toxicity did not
appear
to play
a role in TNF dose limitation (Creaven et al.,
1987; Kimura et al., 1987). Transient thrombocytopenia and
leukopenia have also been observed (Sherman et al., 1988).
changes were seen in haemostatic parameters (Chap-
et al., 1987). Side-effects clear rapidly after discontinu-
ing
TNF administration while the febrile reaction is reduced
by pre-treatment with paracetamol or indomethacin (Moritz
al., 1989). Caution has been recommended in treating
patients with pre-existing hepatic function abnormalities,
hypertension, hypotension or significant obstructive airway
disease (Creaven et al., 1989). In addition, the precise role of
TNF in stimulating the growth of both normal and
leukaemic B cells (Jelinek & Lipskey, 1987; Cordingley et al.,
1988a) needs to be further elucidated and taken into account.
As far as immunological functional parameters of blood
cells from patients receiving recombinant human TNF are
concerned, phase I studies demonstrated that TNF acts in
vivo directly or indirectly on NK cells and monocytes by
either inactivating their functional capacity or by absorbing
the relevant cells to the endothelial cell layer, thus removing
them from circulation (Kist et al., 1988).
Once the time of injection and doses were been standar-
dised, clinical trials were designed. Large studies are currently
underway but, for the time being, no consensus has emerged
from preliminary results concerning the clinical efficacy of
this lymphokine in the treatment of malignancy, little
evidence of TNF anti-tumour activity having been observed
in vivo. Although partial remissions were documented in
individual patients with colon and pancreatic cancer and B
cell lymphomas, only a few clinically significant benefits have
been observed (Blick et al., 1987; Creaven et al., 1989; Herr-
mann, 1989; Moritz et al., 1989; Selby et al., 1987; Sherman
et al., 1988) and the role of TNF as a single agent is not
presently recommended. Perhaps the actual meaning of the
experiences reported to date is not that we are ready for a
widespread application of TNF to the therapy of cancer
patients but that eventually we can successfully manipulate
the cellular immune system in the defense against tumours.
However, we are at the very beginning of this new era of
treatment with biological response modifiers, in particular
using TNF. In fact, while clinical experiences with other
molecules (e.g. INFs and IL-2) are quite well documented
and established, immunotherapy with TNF is still in its
infancy and needs to be standardised, for the time being its
use remaining experimental. A series of studies is now being
undertaken to increase the therapeutic efficacy of TNF treat-
ment.
One of the most promising approaches is represented by
the use of TNF in association with other interleukins, and in
particular with IL-2 since a synergism occurs between TNF-
alpha and IL-2 in the generation of lymphokine activated
killer (LAK) cells (Chouaib et al., 1988; Owen-Schaub et al.,
1988; Matossian-Rogers et al., 1989; Yang et al., 1989). The
interaction between IL-2 and TNF on LAK precursors
results in a reduction of the IL-2 concentration required for
the differentiation of granular lymphocytes into LAK cells.
In fact, the addition of TNF-alpha to peripheral blood lym-
phocytes stimulated with suboptimal IL-2 concentrations can
augment the cytotoxicity to levels observed with 10 times
more IL-2 alone and this of course can limit adverse reac-
tions. Furthermore, TNF-alpha either alone or in combina-
tion with IL-2 has been demonstrated to increase the genera-
tion of specific cytotoxic T lymphocytes (Nakano et al., 1989;
Whiteside et al., 1989). Since the function, but not the tox-
icity, of these two molecules is synergistic, this piece of
information may be clinically adapted to improve the safety
and to achieve therapeutic efficacy of immunotherapy trials
without appreciable toxicity. In view of these possibilities, it
is worth mentioning that once LAK cells are stimulated by
tumour targets they become able to secrete TNF (Chong et
al., 1989). The range of agents that act synergistically with
TNF is not limited to biologicals; chemotherapic drugs may
show similar synergism thus offering choices for clinical test-
ing. However, no clinical data are available to substantiate
these pre-clinical studies.
Other approaches to be considered to identify a regimen of
TNF administration that will induce the desired
immunological effects with acceptable levels of toxicity in-
clude the increase of maximal tolerated dose and prolonged
infusion times which allow the application ofhigher doses. In
this regard, the cell cycle dependence of TNF cytotoxicity in
vitro (Darzynkiewicz et al., 1984) indicates that different
schedules of administration need to be explored accurately to358 G. SEMENZATO
determine whether continuous or interrupted availability of
TNF is more effective. In addition, the possibility to maxi-
mise the accumulation of TNF at the site of tumour growth
must be further explored since some remissions have been
reported with trials of recombinant TNF after direct injec-
tion into the tumour (Taguchi, 1987).
For the time being, the intercellular network of
mechanisms regulating the cytokines circuits in vivo is not
sufficiently understood to allow us to predict the anti-tumour
effect as well as adverse reactions induced by these
immunotherapeutic approaches. The use of lymphokines as
pharmacological agents is probably more complicated than
initially thought (Paul, 1989) and further knowledge of the
physiology of the immune system will undoubtedly shed light
on this issue, thus enabling investigators to validate these
new therapeutic strategies.
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